Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT Study

Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology ENGAGEMENT Study (Virtual Genetics Board)

This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.

Study Overview

• Status: Active, not recruiting
• Conditions: Prostate Carcinoma
• Intervention / Treatment: Other: Survey Administration; Other: Interview; Other: Educational Intervention

Detailed Description

PRIMARY OBJECTIVE:

I. To assess perceived usefulness of a virtual genetics board.

SECONDARY OBJECTIVE:

I. To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge.

OUTLINE:

Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

• Study Type: Observational
• Enrollment (Actual): 118

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Non-genetic providers who perform prostate cancer (PCA) genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)

Description

Inclusion Criteria:

Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study:

• Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer.
• Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers)
• Scientists and researchers
• Advocacy or patient stakeholder organization members

Exclusion Criteria:

• Non-medical providers

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Observational (survey, virtual genetic board, interview); Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

Other: Survey Administration; Complete survey; Other: Interview; Complete interview; Other: Educational Intervention; Attend virtual genetics board; Other Names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Likert scaled perceived usefulness scores of the virtual genetics board	Perceived usefulness will be judged against a benchmark mean score of 5/7.	After virtual genetics board

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Means or changes in means of Likert scaled acceptability/feasibility	Will be summarized by means, standard deviations, and 95% confidence intervals.	Before and after virtual genetics board
Perceived ease of use	Will be summarized by means, standard deviations, and 95% confidence intervals.	After virtual genetics board
Self-efficacy for recommendations	Will be summarized by means, standard deviations, and 95% confidence intervals.	Before and after virtual genetics board
Change in mean scores on 17 genetics knowledge test questions	Will be summarized by means, standard deviations, and 95% confidence intervals.	Baseline up to post-virtual genetics board

Collaborators and Investigators

• Sponsor: Thomas Jefferson University
• Investigators: Principal Investigator: Amy Leader, DrPh, MPH, Thomas Jefferson University

Study record dates

Study Major Dates

• Study Start (Actual): January 21, 2020
• Primary Completion (Estimated): June 24, 2026
• Study Completion (Estimated): June 24, 2026

Study Registration Dates

• First Submitted: February 19, 2021
• First Submitted That Met QC Criteria: March 4, 2021
• First Posted (Actual): March 9, 2021

Study Record Updates

• Last Update Posted (Estimated): October 10, 2025
• Last Update Submitted That Met QC Criteria: October 8, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Health Services; Health Care Facilities Workforce and Services; Child Health Services; Community Health Services; Preventive Health Services; Socioeconomic Factors; Population Characteristics; Methods; Interviews as Topic; Early Intervention, Educational; Educational Status
• Other Study ID Numbers: 20F.936; JT 16041 (Other Identifier: JeffTrial Number); 080-27000-X17501 (Other Grant/Funding Number: DOD)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No